Edesa Biotech (EDSA) Capital Expenditures (2013 - 2022)
Edesa Biotech (EDSA) posted Capital Expenditures of -$41.0 for Q3 2022, down 103.02% sequentially from $1358.0 in Q2 2022, and up 97.2% YoY from -$20.79 in Q3 2021.
Edesa Biotech (EDSA) Capital Expenditures (2013 - 2022) Analysis & Trends
Edesa Biotech has reported Capital Expenditures for 10 years, with the latest figure at -$41.0 in Q3 2022.
- Quarterly Capital Expenditures rose 97.2% year-over-year to -$41.0 in Q3 2022, while the trailing twelve-month figure through Jun 2023 was -$41.0 (down 100.97% YoY) and the FY2022 annual result came in at $5656.0, down 7.97% from the prior year.
- Capital Expenditures fell to -$41.0 in Q3 2022 per EDSA's latest filing, from $1358.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $171124.0 in Q1 2018 and troughed at -$24627.0 in Q3 2020.
- A 5-year average of $13022.4 and a median of $2267.0 in 2019 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 303.1% in 2018, down 90.65% in 2018.
- Over 5 years, Capital Expenditures stood at $5666.0 in 2018, then tumbled by 59.99% to $2267.0 in 2019, then sank by 49.93% to $1135.0 in 2020, then soared by 176.65% to $3140.0 in 2021, then slumped by 101.31% to -$41.0 in 2022.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$41.0, $1358.0, and $1199.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -41.00 |
| Sep 30, 2022 | -41.00 |
| Jun 30, 2022 | 1,358.00 |
| Jun 30, 2022 | 1,358.00 |
| Mar 31, 2022 | 1,199.00 |
| Mar 31, 2022 | 1,199.00 |
| Dec 31, 2021 | 3,140.00 |
| Dec 31, 2021 | 3,140.00 |
| Sep 30, 2021 | -1,464.00 |
| Sep 30, 2021 | -1,464.00 |
| Jun 30, 2021 | 3,512.00 |
| Jun 30, 2021 | 3,512.00 |
| Mar 31, 2021 | 2,963.00 |
| Mar 31, 2021 | 2,963.00 |
| Dec 31, 2020 | 1,135.00 |
| Dec 31, 2020 | 1,135.00 |
| Sep 30, 2020 | -24,627.00 |
| Sep 30, 2020 | -24,627.00 |
| Mar 31, 2020 | 825.00 |
| Mar 31, 2020 | 825.00 |